

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. McLaren Oakland		In accordance with letter dated October 19, 2016	4. Expiration Date: June 30, 2024
2. 50 North Perry Street Pontiac, MI 48342		3. License number: 21-04081-03 is amended in its entirety to read as follows:	5. Docket No.: 030-02041 Reference No.:
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200 C. Any byproduct material permitted by 10 CFR 35.300 D. Iodine-125 permitted by 10 CFR 35.400	7. Chemical and/or physical form A. Any B. Any C. Any D. Sealed Sources (Bard Brachytherapy, Inc. Model STM 1251; Best Medical International, Inc. (formerly Best Industries, Inc.) Model 2301; Medi-Physics, Inc. d/b/a GE Healthcare Models 6711 (OncoSeed) and 6733 (EchoSeed); and Theragenics Corporation Models I-Seed AgX100 and I-Seed I25.S06)	8. Maximum amount that licensee may possess at any one time under this license A. As Needed B. As Needed C. 1 curie total D. 600 millicuries total	9. Authorized use A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. B. For use in imaging and localization studies permitted by 10 CFR 35.200. C. For any use permitted by 10 CFR 35.300. D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
21-04081-03

Amendment No. 58

Docket or Reference Number
030-020416. Byproduct, source, and/or
special nuclear materialE. Palladium-103 permitted
by 10 CFR 35.400

7. Chemical and/or physical form

E. Sealed Sources (Best Medical
International, Inc. (formerly Best
Industries, Inc.) Model 2335 and
Theragenics Corporation Model
TheraSeed 200).8. Maximum amount that licensee
may possess at any one time
under this license

E. 600 millicuries total

9. Authorized use

E. For any manual brachytherapy
procedure permitted by 10 CFR 35.400.**CONDITIONS**

10. A. Licensed material listed in Subitem Nos. 6.A. through 6.E. may be used only at the licensee's facilities located at 50 North Perry Street, Pontiac, Michigan.
- B. License material listed in Subitems 6.A through 6.C. may be used at McLaren Oakland Clarkston Radiology, 6770 Dixie Highway, Suite 100, Clarkston, Michigan.
- C. Licensed material listed in Subitem Nos. 6.A. through 6.C. may be used at the licensee's facilities located at 3550 Pontiac Lake Road, Waterford Michigan.
- D. Licensed material listed in Subitem No. 6.B. (for sentinel node injections only) may also be used or stored at the licensee's facilities located at McLaren Diagnostic Imaging, 5701 Bow Pointe Drive, Clarkson, Michigan.
11. The Radiation Safety Officer (RSO) for this license is Roshan Pai, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
21-04081-03

Amendment No. 58

Docket or Reference Number
030-02041

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User

Creagh E. Milford, D.O.

Adeel Khalid, M.D.

Eli Edward Shapiro, M.D.

Mahmood A. Khalid, M.D.

James Lee Peters, M.D.

Arthur J. Frazier, M.D.

Stephen D. Franklin, M.D.

Roshan Pai, M.D.

John D. Mellen, M.D.

Material and Use

10 CFR 35.100 and 35.200

10 CFR 35.100 and 35.200

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)

10 CFR 35.100, 35.200, and 35.300


10 CFR 35.100, 35.200, and 35.300

10 CFR 35.300 and 35.400

10 CFR 35.400

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100 and 35.200



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
21-04081-03

Amendment No. 58

Docket or Reference Number
030-02041

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated January 16, 2014 (ML14021A094)

B. Letter dated June 27, 2016 (ML16183A331)

C. Letter dated August 19, 2016 (ML16242A198)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: November 14, 2016By: Sara A. ForsterSara A. Forster, M.S.
Materials Licensing Branch
Region III